

AUG 23 2001

TECH CENTER 1600/2900

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PATENT NO.
10058-150

APPLICATION NO.

09/173,531

APPLICANT

Ellison et al.

FILING DATE

October 15, 1998

GROUP

TBA-1616

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	132,275	10/15/1872	Gettings	424	620	
AB	232,807	10/05/1886	Dennett	514	25	
AC	3,700,498	10/24/72	Kanazawa et al.	430	128	
AD	4,497,780	02/05/85	Barin et al.	423	88	
AE	5,759,837	06/02/98	Kuhajda et al.	435	193	
AF	09/180,366		Lu			07/06/98
AG	09/180,965		Warrell, Jr. et al.			11/10/98
AH	08/702,011		Zhang			8/23/96

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
AI		JP 51-88620	03/08/76	Japan (with English abstract)				
AJ		WO 95/01789	01/19/95	PCT				
AK		CN 1133725 A	10/23/96	China (with English abstract)				
AL		CN 1131037 A	09/18/96	China (with English abstract)				
AM		CN 1122700 A	05/22/96	China (with English abstract)				
AN		CN 1081104 A	01/26/94	China (with English abstract)				
AO		CN 1119113 A	03/27/96	China (with English abstract)				
AP		CN 1061908 A	06/17/92	China			✓	
AQ		CN 1121807 A	05/08/96	China			✓	
AR		CN 1079391 A	12/15/93	China			✓	
AS		WO 94/02108	02/03/94	PCT				
AT		FR 2 809 558 A1	06/15/94	France				
AV		WO 95/22336	08/24/95	PCT				
		LV 11667 B	06/20/97	Latvia Republic				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AX	"Arsen (III)-Sulfid As ₂ S ₂ ", Gmelin's Arsenic, 8th. Edition, 17: 422-433, 1952.
AZ	"Goodman & Gilman's The pharmacological basis of therapeutics", ninth edition, McGraw-Hill, Health Professions Division, pp. 1659-1662 (Date not Known).

TECH C

2900



JECH CENTER 1600/2900

BA	"Inorganic Arsenic Compounds Other Than Arsine Health and Safety Guide, Health and Safety Guide No. 70", WHO, Geneva, 1992.
BC	"Xionghuang Realgar", Chinese Pharmacopoeia (I), Guangdong Science And Technology Publishing House, China, pp. 256-258, 1988.
BD	Akao et al., "Arsenic Induces Apoptosis in B-cell Leukemic Cell Lines in Vitro: Activation of Caspases and Down-regulation of Bcl-2 Protein", British J of Hematology, 102: 1055-1060, 1998.
BE	Andre et al., "The PML and PML/RAR α Domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic", Experimental Cell Research, 229: 253-260, 1996.
BF	Arsenic, Environmental Health Criteria 18, Geneva: WHO, 1981.
BG	Chemical Abstract, 63-Pharmaceuticals 11:317, #111: 219272j and 111: 219276p, 1987-1991.
BH	Chen et al., "In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As ₂ O ₃) in the treatment of acute promyelocytic Leukemia: As ₂ O ₃ induces NB ₄ cell apoptosis with down regulation of Bcl-2 expression and modulation of PML-RAR α /PML proteins", Blood 88(3):1052-1061, 1996.
BI	Chen et al., "Use of Arsenic Trioxide (As ₂ O ₃) in the Treatment of Acute Promyelocytic Leukemia (APL): I. As ₂ O ₃ Exerts Dose-Dependent Dual Effects on APL Cells", Blood 89(9):3345-3353, 1997.
BJ	Chung et al., "Influence for Carcinoma Cell and Lymphatic cell of Acetyl Arsonate", Yakhak Hoeji 40(5):599-607, 1996.
BK	Cutler et al., Article IV, American Journal of the Medical Sciences, pp. 74-84.
BL	Cuzick et al., "Medicinal arsenic and internal malignancies", Br. J. Cancer, 45: 904-911, 1982.
BM	promyelocytaires, medecine/sciences, 13: 867-71, 1997.
BN	Dictionary Of Inorganic Compounds, Vol. I, Ac-C ₁₀ , IC-000667-IC-000671.
BO	Flamigni et al., "Effect of Sodium Arsenite on the Induction and Turnover of Ornithine Decarboxylase Activity in Erythroleukemia Cells", Cell Biochemistry and Function 7:213-217, 1989.
BP	Fluka, 1995/96 Catalog:152-153
BQ	Forkner et al., "Arsenic as a therapeutic agent in chronic myelogenous leukemia", Jour. A.M.A. 97(1):3-5, 1931.
BR	Germolec et al., "Arsenic induces over expression of growth factors in human keratinocytes", Toxicology And Applied Pharmacology, 141: 308-318, 1996.
BS	Huang et al. 1995, "The Clinical Study of QINGDAL Tablet For Treating Acute Promyelocytic Leukemia", Chinese Journal of Hematology, 17:20.
BT	Ishinishi N. et al., "Study on Chronic Toxicity of Arsenic Trioxide in Rats with Special Reference to the Liver Damages", Fukuoka Acta Medicine, 71:27, 1980.
BU	Kasper et al., "Hepatic Angiosarcoma and bronchioloalveolar carcinoma induced by Fowler's solution", JAMA 252(24):3407-3408, 1984.
BV	Kerkvliet et al., "Immunotoxicology Studies of Sodium Arsenate-effects of Exposure on Tumor Growth and Cell-mediated Tumor Immunity", J Environmental Pathology and Toxicology, 4:65-79, 1980.
BW	König et al., "Comparative Activity of Melarsoprol and Arsenic Trioxide in Chronic B-Cell Leukemia Lines", Blood 90(2):562-570, 1997.
BX	Kwong et al., "Delicious Poison: Arsenic Trioxide for the treatment of Leukemia", Blood 89:3487-8, 1997.

BX	Lee et al., "Induction of Gene Amplification by Arsenic", Science, 241: 79-81, 1988.
BY	Li et al., "Traditional Chinese and Western Medicine in the Treatment of 27 Patients with Malignant Lymphoma", Chinese J Oncology, 10:61-62, 1988.
BZ	Lu et al., "Effective treatment of AML-M3 (APL) and their remission maintenance with Realgar: A pilot clinical and laboratory study on 38 patients", Blood, 90(10 Suppl. 1, part 1):416A, #1849, 1997.
CA	Lu et al., "Study of Realgar in the treatment of acute promyelocytic Leukemia (APL)- a pilot clinical and laboratory study on 32 Patients, China-Korea Medical Conference '97, 1997.
CB	Mervis, "Ancient remedy performs new tricks", Science 273: 578, 1996.
CC	Monfardini et al., "Survival in chronic myelogenous leukemia: influence of treatment and extent of disease at diagnosis", Cancer, 31: 492-501, 1973.
CD	Neubauer, "Arsenic Cancer: a review", Arsenical Cancer, Arsenic Committee of the Medical Research Council, pp. 192-251, 1947.
CE	Pershagen et al., "On the pulmonary tumorigenicity of arsenic trisulfide and calcium arsenate in hamsters", Cancer Letters, 27: 99-104, 1985.
CF	Pories et al., "Trace Elements that Act to Inhibit Neoplastic Growth", Annals New York Academy of Sciences, 199:pp 265-273, 1972.
	Method for removing As₂O₃ from Realgar, Chung Yao Tung Pao, 8(6): 21-22, 1988.
CH	Reichl et al., "Effect of Arsenic on Cellular Metabolism after Single or Repeated Injection in Guinea Pigs", Arch. Toxicol., Suppl. 13, p. 363-65, 1989.
CI	Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, p. 1570-80, 1990.
CJ	Schenk, Handbook of Preparative Inorganic Chemistry, 1: 603, G. Brauer, Ed., Academic press, New York, 2nd Ed., 1963.
CK	Shen et al., "Use of arsenic trioxide (As ₂ O ₃) in the treatment of acute promyelocytic Leukemia (APL): II. clinical efficacy and pharmacokinetics in relapsed patients", Blood 89(9):3354-3360, 1997.
CL	Shibuya, "Studies on Experimental Arsenious Acid Poisoning", Tokyo Jikeikai Ika Daigaku Zasshi 86(4):653, 1971.
CM	Soignet et al., "Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide", J of Medicine 339:19, 1998.
CN	Stephens et al., "The therapeutic effect of solution of potassium arsenite in chronic myelogenous leukemia", Ann. Intern. Assoc 9:1488-1502, 1936.
CO	Suehiro Shimotsuura et al., "Studies on the Antineoplastic Actions of As ₂ O ₃ ", Shikwa Gakuho 86: 1237-1253, 1986.
	Traditional Chinese and Western Medicine in the Treatment of 22 patients with Acute Promyelocytic Leukemia, Chinese J of Traditional Chinese and Western Medicine 1(3), 1992.
CQ	Treleaven et al., "Arsenic and Ayurveda", Leukemia and Lymphoma 10:343-345, 1993.
CR	USP Dictionary of USAN and International Drug Names, United states Pharmacopeial Conventions, Inc., Rockville, MD, p. 59, November, 1994.
	Studies on chemically preventing leukemia, Chung Hua Chung Liu Tsa Chih, 11(3): 207-210, 1989.
CT	Wang et al., "Studies on chemically preventing leukemia", Chung Hua Chung Liu Tsa Chih, 11(3): 207-210, 1989.

		PLA 20(3):227-229.
CV		Yamamoto et al., "Tumorigenicity of inorganic arsenic compounds following intratracheal instillations to the lungs of hamsters", Int. J. Cancer, 40: 220-223, 1987.
		1988.
		Lymphoma, Chinese J. Oncology, 10:61-62, 1988.
		Zhang et al., "Clinical Study on the Treatment of Acute Promyelocytic Leukemia with '713' and '411' of Traditional Chinese and Western Medicine 4(1):19, 1984.
DA		Zhang et. al., "Treatment of Acute Promyelocytic Leukemia with "713": Clinical Observations and Study of Action Mode on 117 patients", J Harbin Medical Univ. 29(3): 243, 1995.
DB		Zhang et al., "Treatment of Acute Promyelocytic Leukemia with Intravenous Arsenic Trioxide", Chinese J. of Hematology 17(2): 1996.
DC		Zhang et al., "Discussion on methods for removing As involving use of yogurt", Zhongguo Zhongyao Zaahi, 20(9): 537, 1995.
DD		Zhu et al., "Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia", Proc.Natl.Acad.Sci. 94:3978-3983, 1997.
DE		"Letter on Historical Facts Regarding the Development of Ai Ling No. 1 and the Clinical Use of Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia and a Study of it Mechanism," Heilongjiang Branch of the Chinese Medical Association, March 27, 1998.
DF		Wang et al., "Arsenic Trioxide and Melarsprol Induced Programmed cell death in myeloid leukemia cell lines and function in PML and PNL-RAR α Independent Manner," Blood, 92(5):1497-1504, 1998.
EXAMINER		DATE CONSIDERED
		10/18/01
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

RECEIVED
AUG 23 2001
TECH CENTER 1600/2900